Three patients in the control group died of respir
Post# of 148187
(Total Views: 553)
Posted On: 06/02/2020 9:32:47 AM
Re: Coocooburra #36194
Three patients in the control group died of respiratory failure, with 14.3% overall mortality at D28; no patients died in the ruxolitinib group. Ruxolitinib was well tolerated with low toxicities and no new safety signals. Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼